170 related articles for article (PubMed ID: 23638745)
21. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670
[TBL] [Abstract][Full Text] [Related]
22. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Engel AL; Holt GE; Lu H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
[TBL] [Abstract][Full Text] [Related]
24. Toll-like receptor ligands energize peptide vaccines through multiple paths.
Celis E
Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.
Cho EI; Tan C; Koski GK; Cohen PA; Shu S; Lee WT
Head Neck; 2010 Jun; 32(6):700-7. PubMed ID: 19908319
[TBL] [Abstract][Full Text] [Related]
26. Clinical investigations of Toll-like receptor agonists.
Meyer T; Stockfleth E
Expert Opin Investig Drugs; 2008 Jul; 17(7):1051-65. PubMed ID: 18549341
[TBL] [Abstract][Full Text] [Related]
27. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic and therapeutic implications of toll-like receptor ligands.
Hedayat M; Takeda K; Rezaei N
Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
[TBL] [Abstract][Full Text] [Related]
29. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
Wages NA; Slingluff CL; Petroni GR
Contemp Clin Trials; 2015 Mar; 41():172-9. PubMed ID: 25638752
[TBL] [Abstract][Full Text] [Related]
30. Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine.
Taillardet M; Haffar G; Mondière P; Asensio MJ; Pléau-Pison T; Burdin N; Defrance T; Genestier L
J Infect Dis; 2010 Aug; 202(3):470-9. PubMed ID: 20575660
[TBL] [Abstract][Full Text] [Related]
31. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Lévy F; Colombetti S
Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
[TBL] [Abstract][Full Text] [Related]
32. Precision nanoscale patterning of TLR ligands for improved cancer immunotherapy.
Tseng CY; Murtada F; Chou LYT
Cell Rep Methods; 2024 May; 4(5):100782. PubMed ID: 38772343
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses.
Garaude J; Kent A; van Rooijen N; Blander JM
Sci Transl Med; 2012 Feb; 4(120):120ra16. PubMed ID: 22323829
[TBL] [Abstract][Full Text] [Related]
35. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
[TBL] [Abstract][Full Text] [Related]
36. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
Corthals SL; Wynne K; She K; Shimizu H; Curman D; Garbutt K; Reid GS
Br J Haematol; 2006 Feb; 132(4):452-8. PubMed ID: 16412017
[TBL] [Abstract][Full Text] [Related]
37. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
Lahiri A; Das P; Chakravortty D
Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
[TBL] [Abstract][Full Text] [Related]
38. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
[TBL] [Abstract][Full Text] [Related]
39. TLR4 agonists as vaccine adjuvants: a chemist's perspective.
Johnson DA
Expert Rev Vaccines; 2013 Jul; 12(7):711-3. PubMed ID: 23885814
[No Abstract] [Full Text] [Related]
40. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
